Abstract
Purpose of review: The purpose of this study is to analyze the current evidence regarding the use of statins in patients with chronic liver disease and cirrhosis. Recent findings: Chronic liver disease (CLD), cirrhosis, and its complications, including hepatocellular carcinoma (HCC), are significant public health problems. The use of statins in patients with CLD has been a matter of concern, and physicians are often reluctant to its prescription in these patients. This mainly relates to the potential occurrence of drug-induced liver injury. However, newer evidence from pre-clinical and clinical research has shown that statins are drugs with a potentially beneficial impact on the natural history of cirrhosis, on portal hypertension, and in HCC prevention. Summary: In this review, we summarize current evidence regarding the influence of statins in endothelial dysfunction in CLD, their ability to modulate hepatic fibrogenesis, and their vasoprotective effects in portal hypertension; we also focus on existing data about the impact of statins in cirrhosis development, progression, and complications and critically assess the current concerns about its use in patients with CLD.
| Original language | English (US) |
|---|---|
| Article number | 43 |
| Journal | Current Gastroenterology Reports |
| Volume | 19 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 1 2017 |
Fingerprint
Keywords
- Chronic liver diseases
- Cirrhosis
- Drug-induced liver injury
- Hepatocellular carcinoma
- HMG-CoA reductase inhibitors
- Portal hypertension
- Statins
- Variceal bleeding
ASJC Scopus subject areas
- Gastroenterology
Cite this
Use of Statins in Patients with Chronic Liver Disease and Cirrhosis : Current Views and Prospects. / Vargas, Jose Ignacio; Arrese, Marco; Shah, Vijay; Arab, Juan Pablo.
In: Current Gastroenterology Reports, Vol. 19, No. 9, 43, 01.09.2017.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Use of Statins in Patients with Chronic Liver Disease and Cirrhosis
T2 - Current Views and Prospects
AU - Vargas, Jose Ignacio
AU - Arrese, Marco
AU - Shah, Vijay
AU - Arab, Juan Pablo
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Purpose of review: The purpose of this study is to analyze the current evidence regarding the use of statins in patients with chronic liver disease and cirrhosis. Recent findings: Chronic liver disease (CLD), cirrhosis, and its complications, including hepatocellular carcinoma (HCC), are significant public health problems. The use of statins in patients with CLD has been a matter of concern, and physicians are often reluctant to its prescription in these patients. This mainly relates to the potential occurrence of drug-induced liver injury. However, newer evidence from pre-clinical and clinical research has shown that statins are drugs with a potentially beneficial impact on the natural history of cirrhosis, on portal hypertension, and in HCC prevention. Summary: In this review, we summarize current evidence regarding the influence of statins in endothelial dysfunction in CLD, their ability to modulate hepatic fibrogenesis, and their vasoprotective effects in portal hypertension; we also focus on existing data about the impact of statins in cirrhosis development, progression, and complications and critically assess the current concerns about its use in patients with CLD.
AB - Purpose of review: The purpose of this study is to analyze the current evidence regarding the use of statins in patients with chronic liver disease and cirrhosis. Recent findings: Chronic liver disease (CLD), cirrhosis, and its complications, including hepatocellular carcinoma (HCC), are significant public health problems. The use of statins in patients with CLD has been a matter of concern, and physicians are often reluctant to its prescription in these patients. This mainly relates to the potential occurrence of drug-induced liver injury. However, newer evidence from pre-clinical and clinical research has shown that statins are drugs with a potentially beneficial impact on the natural history of cirrhosis, on portal hypertension, and in HCC prevention. Summary: In this review, we summarize current evidence regarding the influence of statins in endothelial dysfunction in CLD, their ability to modulate hepatic fibrogenesis, and their vasoprotective effects in portal hypertension; we also focus on existing data about the impact of statins in cirrhosis development, progression, and complications and critically assess the current concerns about its use in patients with CLD.
KW - Chronic liver diseases
KW - Cirrhosis
KW - Drug-induced liver injury
KW - Hepatocellular carcinoma
KW - HMG-CoA reductase inhibitors
KW - Portal hypertension
KW - Statins
KW - Variceal bleeding
UR - http://www.scopus.com/inward/record.url?scp=85026643973&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026643973&partnerID=8YFLogxK
U2 - 10.1007/s11894-017-0584-7
DO - 10.1007/s11894-017-0584-7
M3 - Review article
VL - 19
JO - Current Gastroenterology Reports
JF - Current Gastroenterology Reports
SN - 1522-8037
IS - 9
M1 - 43
ER -